Skip to content

Identification and characterization of community-dwelling older people with sarcopenia.

Identification and characterization of community-dwelling older people with sarcopenia. - MaSS Pilot (Maastricht Sarcopenia Study)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON37690
Enrollment
12
Registered
2012-07-27
Start date
2012-10-10
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related loss of muscle mass and function - Sarcopenia

Interventions

None listed

Sponsors

Universiteit Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Subjects will be included if they are >= 65 years old, have given informed consent, understand Dutch language and are able to perform a walk test. Subjects from both sexes will be included; no specific distribution is needed.

Exclusion criteria

Exclusion criteria: Active rheumathoid arthritis Post stroke status with evident lingering symptoms (paralysis, loss of motor functions) Diseases of the nervous system like Parkinson and MS Active angina pectoris Dementia Older people in a wheelchair Older people with ICD or pacemaker Older people unable to perform the tests, as judged by the investigator

Design outcomes

Primary

MeasureTime frame
The feasibility of a set of tools to measure sarcopenia and its characteristics. Sarcopenia is defined as low muscle mass in combination with low muscle strength and/or low physical performance. Feasiblity includes among others the time span of the testprocedure and the do-ability of the tests (cut-off: 1/3 of the participants indicates problems/negative attitude).

Secondary

MeasureTime frame
Nutritional status, level of physical activity, frailty, activities of daily living, quality of life and health care costs, feasibility.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)